The diagnostic efficiency of biomarkers in sporadic Creutzfeldt-Jakob disease compared to Alzheimer's disease

Neurobiology of Aging

Volumn 30, Issue 11, 2009, Pages 1834-1841

  Bahl, Justyna Maria Czarna ^a   Heegaard, Niels H H ^a   Falkenhorst, Gerhard ^a   Laursen, Henning ^b   Høgenhaven, Hans ^c   Mølbak, Kåre ^a   Jespersgaard, Cathrine ^a   Hougs, Lotte ^a   Waldemar, Gunhild ^c   Johannsen, Peter ^c   Christiansen, Michael ^a  

^a STATENS SERUM INSTITUT   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c Mental Health Services CPH   (Denmark)

Author keywords

14 3 3 protein; Alzheimer's disease; Biomarker; Cerebrospinal fluid; Creutzfeldt Jakob disease; Neuron specific enolase; Phosphorylated tau; Tau

Indexed keywords

NEURON SPECIFIC ENOLASE; PRION PROTEIN; PROTEIN 14 3 3; TAU PROTEIN; THREONINE;

ALZHEIMER DISEASE; ARTICLE; CONTROLLED STUDY; CREUTZFELDT JAKOB DISEASE; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DISEASE MARKER; FEMALE; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; NERVE DEGENERATION; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; SENSITIVITY AND SPECIFICITY;

14-3-3 PROTEINS; ALZHEIMER DISEASE; BIOLOGICAL MARKERS; CREUTZFELDT-JAKOB SYNDROME; HUMANS; PHOSPHOPYRUVATE HYDRATASE; PRIONS; STATISTICS, NONPARAMETRIC; TAU PROTEINS;

EID: 70049096104     PISSN: 01974580     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2008.01.013     Document Type: Article

References (22)

1. Aksamit Jr. A.J., Preissner C.M., and Homburger H.A. Quantitation of 14-3-3 and neuron-specific enolase proteins in CSF in Creutzfeldt-Jakob disease. Neurology 57 (2001) 728-730
2. Andreasen N., Sjogren M., and Blennow K. CSF markers for Alzheimer's disease: total tau, phospho-tau and Abeta 42. World J. Biol. Psychiatry 4 (2003) 147-155
3. Beaudry P., Cohen P., Brandel J.P., Delasnerie-Laupretre N., Richard S., Launay J.M., and Laplanche J.L. 14-3-3 protein, neuron-specific enolase, and S-100 protein in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. Dement. Geriatr. Cogn. Disord. 10 (1999) 40-46
4. Brown P., Budka H., Cervenakova L., Collie D.A., Green A., Ironside J.W., Knight R., Mackenzie J., Pergami P., Rickets M., Summers D., Will B., Zeidler M., Zerr I., World Health Organization, and Communicable Disease Surveillance and Response. WHO Manual for Surveillance of Human Transmissible Spongiform Encephalopathies Including Variant Creutzfeldt-Jakob Disease (2003), World Health Organization, Communicable Disease Surveillance and Response, Geneva, Switzerland
5. Cuadrado-Corrales N., Jimenez-Huete A., Albo C., Hortiguela R., Vega L., Cerrato L., Sierra-Moros M., Rabano A., Pedro-Cuesta J., and Calero M. Impact of the clinical context on the 14-3-3 test for the diagnosis of sporadic CJD. BMC Neurol. 6 (2006) 25
6. Geschwind M.D., Martindale J., Miller D., DeArmond S.J., Uyehara-Lock J., Gaskin D., Kramer J.H., Barbaro N.M., and Miller B.L. Challenging the clinical utility of the 14-3-3 protein for the diagnosis of sporadic Creutzfeldt-Jakob disease. Arch. Neurol. 60 (2003) 813-816
7. Hampel H., Mitchell A., Blennow K., Frank R.A., Brettschneider S., Weller L., and Moller H.J. Core biological marker candidates of Alzheimer's disease-perspectives for diagnosis, prediction of outcome and reflection of biological activity. J. Neural Transm. 111 (2004) 247-272
8. Hesse C., Rosengren L., Andreasen N., Davidsson P., Vanderstichele H., Vanmechelen E., and Blennow K. Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke. Neurosci. Lett. 297 (2001) 187-190
9. Hesse C., Rosengren L., Vanmechelen E., Vanderstichele H., Jensen C., Davidsson P., and Blennow K. Cerebrospinal fluid markers for Alzheimer's disease evaluated after acute ischemic stroke. J. Alzheimers Dis. 2 (2000) 199-206
10. Hsich G., Kenney K., Gibbs C.J., Lee K.H., and Harrington M.G. The 14-3-3 brain protein in cerebrospinal fluid as a marker for transmissible spongiform encephalopathies. N. Engl. J. Med. 335 (1996) 924-930
11. Huang N., Marie S.K., Livramento J.A., Chammas R., and Nitrini R. 14-3-3 protein in the CSF of patients with rapidly progressive dementia. Neurology 61 (2003) 354-357
12. Hulstaert F., Blennow K., Ivanoiu A., Schoonderwaldt H.C., Riemenschneider M., De Deyn P.P., Bancher C., Cras P., Wiltfang J., Mehta P.D., Iqbal K., Pottel H., Vanmechelen E., and Vanderstichele H. Improved discrimination of AD patients using beta-amyloid(1-42) and tau levels in CSF. Neurology 52 (1999) 1555-1562
13. Kallenberg K., Schulz-Schaeffer W.J., Jastrow U., Poser S., Meissner B., Tschampa H.J., Zerr I., and Knauth M. Creutzfeldt-Jakob disease: comparative analysis of MR imaging sequences. Am. J. Neuroradiol. 27 (2006) 1459-1462
14. Kapaki E., Kilidireas K., Paraskevas G.P., Michalopoulou M., and Patsouris E. Highly increased CSF tau protein and decreased beta-amyloid (1-42) in sporadic CJD: a discrimination from Alzheimer's disease?. J. Neurol. Neurosurg. Psychiatry 71 (2001) 401-403
15. Meissner B., Kortner K., Bartl M., Jastrow U., Mollenhauer B., Schroter A., Finkenstaedt M., Windl O., Poser S., Kretzschmar H.A., and Zerr I. Sporadic Creutzfeldt-Jakob disease: magnetic resonance imaging and clinical findings. Neurology 63 (2004) 450-456
16. Ost M., Nylen K., Csajbok L., Ohrfelt A.O., Tullberg M., Wikkelso C., Nellgard P., Rosengren L., Blennow K., and Nellgard B. Initial CSF total tau correlates with 1-year outcome in patients with traumatic brain injury. Neurology 67 (2006) 1600-1604
17. Otto M., Wiltfang J., Tumani H., Zerr I., Lantsch M., Kornhuber J., Weber T., Kretzschmar H.A., and Poser S. Elevated levels of tau-protein in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. Neurosci. Lett. 225 (1997) 210-212
18. Riemenschneider M., Wagenpfeil S., Vanderstichele H., Otto M., Wiltfang J., Kretzschmar H., Vanmechelen E., Forstl H., and Kurz A. Phospho-tau/total tau ratio in cerebrospinal fluid discriminates Creutzfeldt-Jakob disease from other dementias. Mol. Psychiatry 8 (2003) 343-347
19. Sanchez-Juan P., Green A., Ladogana A., Cuadrado-Corrales N., Saanchez-Valle R., Mitrovaa E., Stoeck K., Sklaviadis T., Kulczycki J., Hess K., Bodemer M., Slivarichova D., Saiz A., Calero M., Ingrosso L., Knight R., Janssens A.C., van Duijn C.M., and Zerr I. CSF tests in the differential diagnosis of Creutzfeldt-Jakob disease. Neurology 67 (2006) 637-643
20. Tschampa H.J., Kallenberg K., Urbach H., Meissner B., Nicolay C., Kretzschmar H.A., Knauth M., and Zerr I. MRI in the diagnosis of sporadic Creutzfeldt-Jakob disease: a study on inter-observer agreement. Brain 128 (2005) 2026-2033
21. Windl O., Giese A., Schulz-Schaeffer W., Zerr I., Skworc K., Arendt S., Oberdieck C., Bodemer M., Poser S., and Kretzschmar H.A. Molecular genetics of human prion diseases in Germany. Hum. Genet. 105 (1999) 244-252
22. Zerr I., Bodemer M., Gefeller O., Otto M., Poser S., Wiltfang J., Windl O., Kretzschmar H.A., and Weber T. Detection of 14-3-3 protein in the cerebrospinal fluid supports the diagnosis of Creutzfeldt-Jakob disease. Ann. Neurol. 43 (1998) 32-40